We collected clinical and mRNA data from 525 GBM patients, and the aggregated patient population from the GBM dataset was dichotomized into those who expressed more Gal-1 than the sample median (n = 394) and those who expressed less Gal-1 than the median (n = 131), the high Gal-1 group portended worse survivorship. The gene discussed is LGALS1; the disease is glioblastoma.